Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Next Previous
Trial Profile

A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Complex partial epilepsy; Generalised seizures; Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Life Science

Most Recent Events

  • 29 Jun 2023 According to an Endo International media release, XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy received approval from Health Canada.
  • 27 Apr 2023 Results of pooled post hoc analysis assessing effects of adjunctive cenobamate and concomitant antiseizure medications (ASMs) on weight from YKP3089C013 , YKP3089C017 and YKP3089C021 presented at the 75th Annual Meeting of the American Academy of Neurology 2023
  • 06 Dec 2022 Results of pooled, Post-hoc analysis from YKP3089C013 , YKP3089C017 and YKP3089C021 , presented at the 76th Annual Meeting of the American Epilepsy Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top